The rapid effector functions and tissue heterogeneity of memory T-cells facilitate protective immunity, but can also promote immunopathology in anti-viral immunity, autoimmunity and transplantation. Modulation of memory T-cells is a promising, but not yet achieved strategy for inhibiting these deleterious effects. Using an influenza infection model, we demonstrate that memory CD4 T-cell-driven secondary responses to influenza challenge result in improved viral clearance yet do not prevent the morbidity associated with viral infection, and exacerbate cellular recruitment into the lung, compared to primary responses. Inhibiting CD28 costimulation with the approved immunomodulator, CTLA4Ig, suppressed primary responses in naive mice infected with influenza, but was remarkably curative for memory CD4 T-cellmediated secondary responses to influenza, with reduced immunopathology and enhanced recovery. We demonstrate that CTLA4Ig differentially affects lymphoid and non-lymphoid responses to influenza challenge, inhibiting proliferation and egress of lymphoid naive and memory T-cells, while leaving lung-resident memory CD4 T-cell responses intact. Our findings reveal the dual nature of memory T-cell-mediated secondary responses, and suggest costimulation modulation as a novel strategy to optimize anti-viral immunity by limiting the memory T-cell response to its protective capacities.
INTRODUCTION
The ability of memory T-cells to mediate rapid effector function and reside in diverse tissue sites, results in recall responses that are kinetically, functionally, and spatially distinct from primary responses initiated by naive T-cells. These unique properties of memory T-cells enable them to mediate protective immunity, yet can also predispose them to promote immunopathology in anti-viral immunity (1, 2) , autoimmunity (3) , and transplantation (4) .
Regulation of memory T-cell-mediated responses is therefore a critical consideration for T-celldirected immunotherapies, to optimize their protective abilities, and inhibit deleterious consequences. However, inhibiting pathways that control or suppress naive T-cell responses have been shown to be either ineffective or differentially effective with memory T-cells (5, 6) , and clinical immunomodulation of memory T-cells in disease has not yet been achieved.
The CD28 costimulatory pathway is required for activation of naive T-cells and has emerged as a key target for immunotherapy. CTLA4Ig (Abatacept) is the first approved costimulation modulator that inhibits the CD28 pathway by binding its ligands CD80 and CD86 with high affinity (7) . CD28 costimulation was previously thought to be dispensable for memory T-cell activation, based on memory T-cell activation in the absence of B7 ligands (8, 9) . maintains enhanced and rapid lung viral clearance mediated by memory CD4 T cells, yet reduces lung immunopathology. In vivo, CTLA4Ig inhibits naive and memory CD4 T-cell lymphoid responses and T-cell recruitment to the lung, while not affecting in situ lung-specific memory Tcell responses, accounting for differential effects on primary versus secondary responses. These results suggest a new strategy to optimize anti-viral immunity to influenza and other ubiquitous pathogens where memory T-cells readily develop and persist, and further emphasize the importance of the host immune status in determining the outcome of immunotherapies. 
MATERIALS AND METHODS

Mice
Reagents
The following purified antibodies were purchased from BioXcell (West Lebanon, NH):
anti-CD8 (TIB 105), anti-CD4 (GK1.5), anti-I-A d (212.A1), and anti-Thy-1 (TIB 238). The 6.5
anti-clonotype antibody directed against the HA-TCR (23) was purified and conjugated to biotin (Pierce, Rockford, IL). Allophycocyanin-or PE-conjugated CD62L, PE-conjugated CD90.1 and CD90.2, FITC-conjugated CD90.1 and CD90.2 and PerCP-conjugated anti-CD4 were purchased from BD Pharmingen (San Diego, CA). PE-conjugated FoxP3 antibody was purchased from eBioscience. Murine CTLA4Ig was obtained from Bristol Myers-Squibb (Princeton, NJ), and murine IgG2a isotype control was obtained from BioExpress. Influenza HA peptide (110-120, SFERFEIFPKE) was synthesized by the Biopolymer Laboratory at the University of Maryland School of Medicine.
Influenza virus infection
Influenza virus (A/PR/8/34) was generously provided by Dr. Walter Gerhard (Wistar Institute) and grown in the allantoic fluid of 10-day old embryonated chicken eggs as described (24). Determination of influenza viral titers in viral stocks, lung homogenates, or BAL was accomplished by the Tissue Culture Infectious Dose 50 assay (TCID 50 ) as described (25) For in vivo infection using sublethal doses of influenza, mice were anesthetized with isoflurane, and 20μl PR8 influenza virus containing 500 TCID 50 was administered intranasally.
For lethal influenza infection, mice were infected as above with 5000 TCID 50 PR8 Influenza (2LD 50 ), and weight loss and mortality monitored daily. All infected mice were housed in the biocontainment suite at the UMB animal facility, where tissue harvest from infected mice was also performed. Isolation of bronchoalveolar lavage (BAL) fluid was obtained from anesthetized mice by flushing the alveolar space with PBS followed by withdrawal of lavage liquid. BAL fluid samples were centrifuged to pellet cells, and the supernatant was analyzed for viral content by the TCID 50 assay described above.
Hemagglutination Inhibition (HI) Assay
The concentration of neutralizing anti-influenza antibodies was measured in serum from 10-day infected animals using the hemagglutination inhibition assay as described (26). Briefly, serum was heat inactivated for 30mins at 56 o C, diluted 1:5 in PBS and preadsorbed with 1%
chicken red blood cells for 30mins. Serial two-fold diltutions of serum were subsequently incubated in duplicate wells with 4 agglutinating units of virus for 1 hour at room temperature, then 50μl of a 1% chicken red blood cell solution was then added to each well and incubated for 45mins at room temperature. The HI titer was expressed as the reciprocal of the serum dilution where agglutination was inhibited in duplicate wells.
Generation of influenza-specific memory CD4 T-cells
Generation of HA-specific memory CD4 T-cells in congenic BALB/c(Thy1.1) hosts was accomplished as previously described (27, 28). Briefly, naive CD4 T-cells were purified from spleens of HA-TCR mice and primed in vitro by culture with 5.0μg/ml HA peptide and mitomycin C-treated, T-depleted BALB/c splenocytes as antigen presenting cells (APC) in complete Clicks media (Irvine scientific, Irvine, CA) for 3 days at 37˚C. The resultant activated HA-specific effector cells were transferred into congenic BALB/c(Thy1.1) hosts (5X10 6 cells/mouse) to yield "HA-memory" mice with a stable population of HA-specific memory CD4
T-cells (27-29). HA-specific memory CD4 T-cells were also generated by transfer of 5X10 6 primed, HA-specific effector cells into RAG2 -/-recipient mice and harvested 2-3 months posttransfer as previously described (12, 27, 30, 31) . HA-specific memory CD4 T-cells isolated from these RAG2 -/-recipients were labeled with 5μM CFSE (Invitrogen, Carlsbad, CA), and adoptively transferred into secondary BALB/c(Thy1.1) hosts which were subsequently infected with influenza.
Polyclonal memory CD4 T-cells specific for influenza were generated by infecting BALB/c mice intranasally with 500 TCID 50 PR8 influenza. Total splenic CD4 T-cells containing influenza virus specific memory CD4 T-cells were harvested 12-16 weeks post infection. The relative frequencies of influenza-specific IFN-γ and IL-2-secreting memory CD4 T-cells in response to stimulation with HA peptide or whole influenza virus particles were determined using ELISPOT as previously described (27, 31), and spots were enumerated using the Immunospot ELISPOT reader (CTL, Becton Dickinson).
Flow cytometry and Intracellular Cytokine Staining (ICS)
Cells were stained with fluorochrome-conjugated antibodies as described (12) , fixed and acquired using an LSRII flow cytometer (BD, San Jose CA) with a minimum acquisition of 100,000 events and analyzed using FACSDiva software (BD, San Jose CA). Intracellular cytokine staining was performed as described previously (27). Briefly, lymphocytes from the spleen and lungs of influenza infected mice treated with CTLA4Ig or IgG2a were isolated 6-days post-infection, cultured in vitro for 4hrs in the presence of PMA (25ng/ml), Ionomycin (1μg/ml) and monensin (1μl/ml) (Golgi stop, BD Pharmingen), surface stained, fixed in Cytoperm/Cytofix solution (BD Pharmingen), and stained intracellularly with IFN-γ or Isotype control IgG1 antibody in permwash solution (BD Pharmingen). Stained cells were analyzed using an LSRII flow cytometer and FACSDiva software (BD San Jose, CA).
Histopathology of lung samples
For preparation and isolation of lung tissue for histological examination, mice were euthanized by isofluorane inhalation, trachea exposed and lungs were inflated with 4% paraformaldehyde (PFA) at constant pressure. Lungs were then removed from the chest cavity, fixed in PFA, embedded in paraffin wax, sectioned and stained with Hematoxylin and Eosin (H&E) by the pathology core facility (UMB), and analyzed by light microscopy.
In vivo BrdU Labeling
Influenza virus infected mice treated with CTLA4Ig or IgG2a were administered BrdU (1mg, i.p.) for 3 consecutive days starting at day 3 post-infection. Spleen and lung lymphocytes were harvested at day 6 post-infection and resuspended in stain buffer. Cells were surface stained, fixed and permeabilized (Cytofix/Cytoperm, Perm/Wash; BD Biosciences), incubated with DNase (Sigma-Aldrich), and stained intracellularly with fluorescently-labeled anti-BrdU antibodies at 4°C. Cells were subsequently analyzed on the LSRII (BD Biosciences).
Statistics
Results are expressed as the mean value from individual groups +/-the standard deviation indicated by error bars. Significance between experimental groups was determined by the twotailed student T test, assuming a normal distribution for all groups. We assessed whether influenza-specific memory CD4 (Fig. 1A, left ), yet had a highly significant (>2 log) decrease in lung viral titers compared to infected naive mice (Fig. 1A, right) . The rapid viral clearance in HA-memory mice was apparent as early as day 3-post-infection, with near complete clearance by day 7, contrasting naive infected mice with significant viral loads at day 7
RESULTS
Model
and complete viral clearance only by day 10 (Fig. 1B) . We obtained similar results following influenza challenge of polyclonal flu-memory compared to naive mice, which exhibited reduced lung viral titers at day 6 post-infection (Fig. 1C ), yet comparable weight loss through the course of infection (data not shown). The extent of enhanced viral clearance seen with polyclonal memory CD4 T cells was typically lower than for HA-specific memory CD4 T cells due to their lower frequency in a polyclonal T cell population. Together, these results indicate that influenza-specific memory CD4 T-cells can direct a classic secondary immune response to influenza challenge with enhanced kinetics of viral clearance; however, they do not appear to protect against the morbidity of viral infection as measured by weight loss.
CTLA4Ig treatment improves the clinical outcome of memory CD4 T-cell responses to influenza challenge while maintaining viral clearance
We compared the effects of inhibiting CD28 costimulation using CTLA4Ig, on the physiological outcomes of primary and memory T-cell responses to influenza challenge. 
CTLA4Ig treatment of memory mice reduces lung immunopathology
The comparable viral clearance, yet disparate clinical outcomes in CTLA4Ig versus IgG2a-treated, flu-infected memory mice, prompted examination of lung pathology in these differently treated groups following influenza challenge. We examined H&E-stained sections from influenza-infected naive, IgG2a-or CTLA4Ig-treated HA-memory and polyclonal flumemory mice. As compared to uninfected mice, lungs from infected naive mice contained mononuclear infiltrates within the interstitial tissue and near the large airways along with moderate airway damage characterized by hypertrophy in the alveolar epithelium. In addition, these mice had moderate epithelial hypertrophy with dispersed consolidation surrounding the bronchial airways (Fig. 5A ). By contrast, lungs from influenza-challenged control mice with either HA-specific or polyclonal flu-specific memory CD4 T-cells had extensive diffuse mononuclear infiltrates around the airways and throughout the interstitium leading to disruption of normal alveolar architecture and severe consolidation near most of the bronchial airways. In tandem, we observed acute damage to the airway epithelium as evidenced by desquamation throughout the alveoli and sloughing within the bronchial airways ( We also investigated whether there were increased numbers of CD8 T cells in the lungs of flumemory mice and whether CD8 T cell recruitment to the lungs was affected by CTLA4Ig .
Interestingly, we found a decreased number of CD8 T cells in the lungs of flu-infected memory compared to naive mice (Fig. 5D ), possibly due to reduced CD8 T cell priming due to early lung viral clearance in HA-memory mice (Fig. 1B) . These results indicate that increased CD8 T cell recruitment to the lung does not occur in the presence of flu-specific memory CD4 T cells.
Moreover, CTLA4Ig treatment did not significantly decrease or alter the number of CD8 T cells in the lungs of influenza-infected naive or memory hosts. (Fig. 5D ). These results show that CTLA4Ig has more profound inhibitory effects on the endogenous CD4 compared to the CD8 T cell compartment during influenza virus infection.
CTLA4Ig reduces the accumulation and expansion of memory CD4 T-cells in spleen and lung following influenza challenge
In hosts were CFSE labeled and transferred to mice treated and infected as in Fig. 2A . We found extensive in vivo proliferation of HA-specific memory T-cells in both IgG2a-and CTLA4Ig-treated groups; however, the proportion and absolute numbers of minimally divided (CFSEhi)
CD4 T-cells was higher in CTLA4Ig-compared to control-treated mice (Fig. 6B) . These results (Fig. 7A) .
Interestingly, HA-specific memory CD4 T-cells in the lung of both IgG2a and CTLA4Ig-treated infected mice were predominantly CD62Llo (Fig. 7A) , indicating that CTLA4Ig did not effect the CD62L profile of lung memory CD4 T-cells and rather had biased effects on CD62L
expression by spleen memory CD4 T-cells.
The predominant CD62Lhi phenotype of splenic memory CD4 T-cells in CTLA4Ig-treated flu-infected mice could result from impaired memory CD4 T-cell activation, or reduced CD62L downregulation by activated memory T-cells. To address these possibilities, we
analyzed the CD62L profile of CFSE-labeled HA-specific memory CD4 T-cells transferred into differentially treated mice as in Fig. 6B . This analysis clearly shows that maximally divided memory CD4 T-cells (CFSElo) were predominantly CD62Llo in control-treated mice, and were equally divided between CD62Lhi and CD62Llo phenotypes in CTLA4Ig-treated mice (Fig. 7B ).
These results indicate that CTLA4Ig partially inhibits CD62L downregulation on memory CD4
T-cells responding to influenza virus, suggesting that the capacity of lymphoid memory CD4 Tcells to home to non-lymphoid sites, such as the lung, is curtailed.
CTLA4Ig treatment has biased effects on lymphoid memory CD4 T-cells
In order to evaluate the cellular mechanism for the differential effects of CTLA4Ig treatment on primary and secondary immune responses to influenza infection, we analyzed in vivo responses of naive and memory CD4 T-cells in both lymphoid and non-lymphoid tissues, by
BrdU incorporation. We administered BrdU to naive or HA-memory mice infected and treated as in Fig. 2A , harvested spleen and lung tissue 6 days post-infection, and measured the extent of BrdU incorporation in each tissue from the differentially treated groups. In naive mice infected with influenza, BrdU incorporation of endogenous CD4 T cells in both the spleen and lung of control-treated mice was substantially inhibited by CTLAIg treatment (Fig. 7A) , with mockinfected controls having minimal BrdU incorporation in both tissues (0.5-1% and 1-3% in spleen and lung, respectively). In flu-infected HA-memory mice, both spleen and lung-resident memory CD4 T-cells in control-treated mice exhibited extensive BrdU incorporation following influenza infection (Fig. 8B, left) , that exceeded BrdU incorporation in the primary CD4 T cell response (Fig. 8A ). In the presence of CTLA4Ig, BrdU incorporation by spleen memory CD4 Tcells was markedly reduced (five-fold reduction), whereas BrdU incorporation by lung-memory CD4 T-cells, was not affected (Fig. 8B , top left and bottom left). Brdu incorporation of endogenous CD4 and CD8 T cells in spleen and lung of infected memory mice was inhibited by CTLA4Ig treatment, similar to that seen in naive mice (data not shown). These results strongly suggest that CTLA4Ig preferentially inhibits spleen or lymphoid-derived naive and memory CD4
T-cells, while leaving intact in situ lung memory CD4 T-cells responses; however, we cannot rule out that BrdU + cells in the lung may have migrated from lymphoid sites.
A hallmark of memory CD4 T cell recall is their rapid effector function. We therefore measured the capacity of HA-memory CD4 T cells recovered from the spleen and lung of CTLA4Ig-or IgG2a-treated mice to produce IFN-γ 6-days post influenza virus challenge. We observed a biased reduction in early IFN-γ production from spleen memory CD4 T cells (twofold) of CTLA4Ig-treated mice, with no significant reduction in IFN-γ production from lungresident memory CD4 T cells (Fig. 9A) . These results show that inhibition of CD28 costimulation differentially affects rapid cytokine secretion from lymphoid and non-lymphoid memory CD4 T cells.
Our findings that lung memory CD4 T-cells retain effector function in the presence of
CTLA4Ig in vivo, suggested either that the functional recall of lung memory CD4 T-cells was independent of CD28, or that CTLA4Ig was not present in sufficient quantities in the lung in vivo. To distinguish between these possibilities, we examined the functional properties of antigen-specific lung memory CD4 T cells in vitro in the presence of ample quantities of CTLA4Ig. We found that lung memory CD4 T-cells produce predominantly IFN-γ and to a lesser extent IL-2 following antigenic stimulation (Fig. 9B) . Antigenic stimulation of lungmemory CD4 T cells in the presence of CTLA4Ig resulted in significant inhibition of IL-2, while IFN-γ production was unchanged from control-treated antigen-stimulated cells (Fig. 9B) . When taken together, our results demonstrate that effector function from lung memory CD4 T cells is intrinsically independent of CD28 costimulation.
DISCUSSION
We demonstrate here that memory CD4 T-cells mediate secondary responses to influenza infection characterized by efficient viral clearance in the context of extensive immunopathology and morbidity. Strikingly, the physiological outcome of a memory CD4 Tcell-mediated secondary response to influenza can be significantly improved by targeting the CD28 pathway with the costimulation modulator CTLA4Ig. While CTLA4Ig is suppressive for primary immune responses to influenza, leading to increased viral loads, reduced lung function and increased morbidity-CTLA4Ig treatment of memory CD4 T-cell secondary responses to influenza is remarkably curative, resulting in less morbidity and immunopathology, and
enhanced recovery. We demonstrate that CTLA4Ig specifically inhibits lymphoid memory CD4
T cell responses, and reduces their capacity to migrate to non-lymphoid sites. Moreover, the ability of lung memory T cells to respond to influenza in situ and mediate rapid effector function is independent of CD28 costimulation, and remains intact in CTLA4Ig-treated mice. Our results reveal a novel role for CD28-based immunotherapy for optimizing anti-viral secondary responses by differential effects on lymphoid versus lung memory CD4 T-cells.
Our findings that CTLA4Ig treatment resulted in disparate clinical outcomes for primary and secondary responses to influenza can be attributed to the disparate functional and spatial attributes of primary and memory responses. Naive T-cells reside and become activated in lymphoid tissue and require CD28 costimulation for IL-2 production, and differentiation into effector cells (38, 39) , which will ultimately migrate to the site of infection. CTLA4Ig-treatment of naive mice infected with influenza suppressed the initiation of T-cell and antibody responses in lymphoid clearance, impairing the anti-viral response. By contrast, memory CD4 T-cells are present in both lymphoid and lung tissue, and require CD28 costimulation mainly for antigen-driven IL-2 production and proliferation (12) . While CTLA4Ig inhibited lymphoid memory CD4 T-cell expansion, it did not affect in situ lung memory CD4 T-cell expansion and effector cytokine production, and therefore viral clearance was maintained. Our results further reveal a specific role for CD28 costimulation in homing to non-lymphoid sites during a viral infection, and are consistent with earlier findings that CD28 controls T-cell migration to peripheral sites in the absence of infection (40) . These effects of CTLA4Ig treatment on T-cell homing may be a mechanism for the clinical efficacy of Abatacept in reducing immunopathology in rheumatoid arthritis, known to be perpetuated by memory CD4 T-cells (14) .
In addition to its differential effects on lymphoid and non-lymphoid responses, CTLA4Ig treatment had disparate effects on cytokine production by memory CD4 T cells. We show here that CTLAIg preferentially inhibits IL-2 production from lung memory CD4 T cells, while leaving intact IFN-γ production. We propose that the ability of CTLA4Ig to differentially inhibit IL-2 versus IFN-γ responses may be directly related to the uncoupling of immunopathology and protection in secondary influenza responses. IFN-γ production has been shown to be crucial for protection in secondary responses to influenza and other viral infections (41, 42) , although it can be dispensible for clearance of influenza virus during primary responses (43, 44) . The ability of lung memory CD4 T-cells to rapidly produce IFN-γ in the presence of CTLA4Ig despite a suppressed antibody and endogenous CD4 and CD8 T cell response, suggest that IFN-γ production in situ may mediate rapid viral clearance by memory CD4 T cells-a possibility we are currently investigating. Conversely, IL-2 production by memory CD4 T cells, which is important for their expansion (12) , can contribute to increased infiltration into lung tissue and the resultant immunopathology. Thus, highly expansive memory T cells may be detrimental when site-specific immunity is required in respiratory virus infections. We propose that for protective immunity to influenza, the quality and location of memory T-cells is more important than their absolute frequency-also a key issue for vaccine design (45) .
We demonstrate that targeting CD28 costimulation can optimize influenza-specific anti- 
